BRISTOL-MYERS SQUIBB COMPANY OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax of -$2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2026-06-30 was -$2.00M, a 300.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2026-03-31 was -$4.00M, a 500.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-06-30 was $1.00M.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for the quarter ending 2025-03-31 was $1.00M.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2022 was -$2.00M.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2021 was -$11.00M, a 283.33% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2020 was $6.00M, a 86.67% decline from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), after adjustment, before tax for fiscal 2019 was $45.00M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.00M 10-Q · filed 2026-07-30 | -$5.00M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | -$4.00M 10-Q · filed 2026-04-30 | |||
| 2025-06-30 | $1.00M 10-Q · filed 2026-07-30 | $1.00M 10-Q · filed 2026-07-30 | ||
| 2025-03-31 | $1.00M 10-Q · filed 2026-04-30 | |||
| 2024-09-30 | $7.00M 10-Q · filed 2024-10-31 | $6.00M derived: sum of 2 quarters · filed 2024-10-31 | $4.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$1.00M 10-Q · filed 2024-07-26 | -$3.00M 10-Q · filed 2024-07-26 | ||
| 2024-03-31 | -$2.00M 10-Q · filed 2025-04-24 | |||
| 2023-09-30 | -$3.00M 10-Q · filed 2024-10-31 | -$3.00M 10-Q · filed 2024-10-31 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-04-25 | $0.00 derived: sum of 2 quarters · filed 2024-04-25 | $0.00 derived: sum of 3 quarters · filed 2024-04-25 | $0.00 derived: sum of 4 quarters · filed 2024-04-25 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 derived: sum of 3 quarters · filed 2023-10-26 | -$2.00M 10-K · filed 2023-02-14 |
| 2022-09-30 | $0.00 10-Q · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | -$2.00M 10-Q · filed 2023-10-26 | -$4.00M derived: sum of 4 quarters · filed 2023-10-26 |
| 2022-06-30 | $0.00 10-Q · filed 2023-07-27 | -$2.00M 10-Q · filed 2023-07-27 | -$4.00M derived: sum of 3 quarters · filed 2023-07-27 | -$7.00M derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-03-31 | -$2.00M 10-Q · filed 2023-04-27 | -$4.00M derived: sum of 2 quarters · filed 2023-04-27 | -$7.00M derived: sum of 3 quarters · filed 2023-04-27 | -$10.00M derived: sum of 4 quarters · filed 2023-04-27 |
| 2021-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$5.00M derived: sum of 2 quarters · filed 2023-02-14 | -$8.00M derived: sum of 3 quarters · filed 2023-02-14 | -$11.00M 10-K · filed 2023-02-14 |
| 2021-09-30 | -$3.00M 10-Q · filed 2022-10-26 | -$6.00M derived: sum of 2 quarters · filed 2022-10-26 | -$9.00M 10-Q · filed 2022-10-26 | -$12.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$3.00M 10-Q · filed 2022-07-27 | -$6.00M 10-Q · filed 2022-07-27 | -$9.00M derived: sum of 3 quarters · filed 2023-02-14 | -$13.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$3.00M 10-Q · filed 2022-04-29 | -$6.00M derived: sum of 2 quarters · filed 2023-02-14 | -$10.00M derived: sum of 3 quarters · filed 2023-02-14 | $1.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$7.00M derived: sum of 2 quarters · filed 2023-02-14 | $4.00M derived: sum of 3 quarters · filed 2023-02-14 | $6.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$4.00M 10-Q · filed 2021-10-27 | $7.00M derived: sum of 2 quarters · filed 2021-10-27 | $9.00M 10-Q · filed 2021-10-27 | $9.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $11.00M 10-Q · filed 2021-07-28 | $13.00M 10-Q · filed 2021-07-28 | $13.00M derived: sum of 3 quarters · filed 2022-02-09 | $19.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $2.00M 10-Q · filed 2021-04-29 | $2.00M derived: sum of 2 quarters · filed 2022-02-09 | $8.00M derived: sum of 3 quarters · filed 2022-02-09 | $21.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $6.00M derived: sum of 2 quarters · filed 2022-02-09 | $19.00M derived: sum of 3 quarters · filed 2022-02-09 | $45.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $6.00M 10-Q · filed 2020-11-05 | $19.00M derived: sum of 2 quarters · filed 2020-11-05 | $45.00M 10-Q · filed 2020-11-05 | $51.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $13.00M 10-Q · filed 2020-08-06 | $39.00M 10-Q · filed 2020-08-06 | $45.00M derived: sum of 3 quarters · filed 2021-02-10 | $49.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $26.00M 10-Q · filed 2020-05-07 | $32.00M derived: sum of 2 quarters · filed 2021-02-10 | $36.00M derived: sum of 3 quarters · filed 2021-02-10 | $28.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $10.00M derived: sum of 2 quarters · filed 2021-02-10 | $2.00M derived: sum of 3 quarters · filed 2021-02-10 | -$30.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $4.00M 10-Q · filed 2019-10-31 | -$4.00M derived: sum of 2 quarters · filed 2019-10-31 | -$36.00M 10-Q · filed 2019-10-31 | -$53.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | -$8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | -$40.00M 10-Q · filed 2019-07-25 | -$57.00M derived: sum of 3 quarters · filed 2020-02-24 | -$30.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | -$32.00M 10-Q · filed 2019-04-25 | -$49.00M derived: sum of 2 quarters · filed 2020-02-24 | -$22.00M derived: sum of 3 quarters · filed 2020-02-24 | -$10.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $10.00M derived: sum of 2 quarters · filed 2020-02-24 | $22.00M derived: sum of 3 quarters · filed 2020-02-24 | $31.00M 10-K · filed 2020-02-24 |
| 2017-09-30 | $27.00M 10-Q · filed 2018-10-25 | $39.00M derived: sum of 2 quarters · filed 2018-10-25 | $48.00M 10-Q · filed 2018-10-25 | $6.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $12.00M 10-Q · filed 2017-07-27 | $21.00M 10-Q · filed 2017-07-27 | -$21.00M derived: sum of 3 quarters · filed 2019-02-25 | -$33.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $9.00M 10-Q · filed 2017-04-27 | -$33.00M derived: sum of 2 quarters · filed 2019-02-25 | -$45.00M derived: sum of 3 quarters · filed 2019-02-25 | -$1.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | -$42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$54.00M derived: sum of 2 quarters · filed 2019-02-25 | -$10.00M derived: sum of 3 quarters · filed 2019-02-25 | $17.00M 10-K · filed 2019-02-25 |
| 2016-09-30 | -$12.00M 10-Q · filed 2017-10-26 | $32.00M derived: sum of 2 quarters · filed 2017-10-26 | $59.00M 10-Q · filed 2017-10-26 | $22.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $44.00M 10-Q · filed 2017-07-27 | $71.00M 10-Q · filed 2017-07-27 | $34.00M derived: sum of 3 quarters · filed 2018-02-13 | $10.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $27.00M 10-Q · filed 2017-04-27 | -$10.00M derived: sum of 2 quarters · filed 2018-02-13 | -$34.00M derived: sum of 3 quarters · filed 2018-02-13 | -$65.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | -$37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$61.00M derived: sum of 2 quarters · filed 2018-02-13 | -$92.00M derived: sum of 3 quarters · filed 2018-02-13 | -$68.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | -$24.00M 10-Q · filed 2016-10-27 | -$55.00M derived: sum of 2 quarters · filed 2016-10-27 | -$31.00M 10-Q · filed 2016-10-27 | -$15.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | -$31.00M 10-Q · filed 2016-07-28 | -$7.00M 10-Q · filed 2016-07-28 | $9.00M derived: sum of 3 quarters · filed 2017-02-21 | -$26.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $24.00M 10-Q · filed 2016-04-28 | $40.00M derived: sum of 2 quarters · filed 2017-02-21 | $5.00M derived: sum of 3 quarters · filed 2017-02-21 | $29.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | -$19.00M derived: sum of 2 quarters · filed 2017-02-21 | $5.00M derived: sum of 3 quarters · filed 2017-02-21 | $9.00M 10-K · filed 2017-02-21 |
| 2014-09-30 | -$35.00M 10-Q · filed 2015-10-27 | -$11.00M derived: sum of 2 quarters · filed 2015-10-27 | -$7.00M 10-Q · filed 2015-10-27 | -$10.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $24.00M 10-Q · filed 2015-07-23 | $28.00M 10-Q · filed 2015-07-23 | $25.00M derived: sum of 3 quarters · filed 2016-02-12 | $44.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $4.00M 10-Q · filed 2015-04-28 | $1.00M derived: sum of 2 quarters · filed 2016-02-12 | $20.00M derived: sum of 3 quarters · filed 2016-02-12 | -$42.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $16.00M derived: sum of 2 quarters · filed 2016-02-12 | -$46.00M derived: sum of 3 quarters · filed 2016-02-12 | -$43.00M 10-K · filed 2016-02-12 |
| 2013-09-30 | $19.00M 10-Q · filed 2014-10-24 | -$43.00M derived: sum of 2 quarters · filed 2014-10-24 | -$40.00M 10-Q · filed 2014-10-24 | -$58.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$62.00M 10-Q · filed 2014-07-24 | -$59.00M 10-Q · filed 2014-07-24 | -$77.00M derived: sum of 3 quarters · filed 2015-02-13 | -$48.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $3.00M 10-Q · filed 2014-04-29 | -$15.00M derived: sum of 2 quarters · filed 2015-02-13 | $14.00M derived: sum of 3 quarters · filed 2015-02-13 | $32.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $11.00M derived: sum of 2 quarters · filed 2015-02-13 | $29.00M derived: sum of 3 quarters · filed 2015-02-13 | $9.00M 10-K · filed 2015-02-13 |
| 2012-09-30 | $29.00M 10-Q · filed 2013-10-23 | $47.00M derived: sum of 2 quarters · filed 2013-10-23 | $27.00M 10-Q · filed 2013-10-23 | |
| 2012-06-30 | $18.00M 10-Q · filed 2013-07-25 | -$2.00M 10-Q · filed 2013-07-25 | ||
| 2012-03-31 | -$12.00M 10-Q · filed 2013-04-25 | |||
| 2011-12-31 | $35.00M 10-K · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |